Crucell, GSK to develop malaria vaccine

Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) partnered to develop a second-generation malaria vaccine. Crucell will contribute its AdVac Ad35-CS recombinant malaria vaccine, and GSK will contribute its Mosquirix malaria vaccine. Ad35-CS, which is based on Crucell's AdVac adenovirus technology, is in Phase I trials in the U.S. Mosquirix, which uses RTS,S peptide and TRAP sporozoite antigen together with the QS-21 Stimulon adjuvant from Antigenics Inc. (NASDAQ:AGEN), is in Phase III testing. ...